The lupus therapeutic market is estimated to be valued at US$ 3035.59 Mn in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
The lupus therapeutic market consists of drugs used for the treatment of lupus erythematosus. Lupus is an autoimmune disease where the immune system mistakenly attacks healthy tissues in different parts of the body such as joints, skin, kidneys, blood cells, brain, heart and lungs. Some key products in this market are antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, immunosuppressants and biologics. These drugs help reduce symptoms, prevent damage to internal organs and improve quality of life.

Market Dynamics:
The lupus therapeutic market is primarily driven by the increasing prevalence of lupus globally. According to the Lupus Foundation of America, around 1.5 million Americans and at least 5 million people globally have a form of lupus. The prevalence is higher among women, especially in the childbearing years. The other major driver is the rising healthcare expenditure in emerging countries such as China and India. Adequate healthcare funding is supporting advanced drug discovery and new product launches in these countries. However, the market growth can be restrained by the high costs of biologics and lack of awareness about lupus in low-income regions. Also, side effects associated with long-term usage of corticosteroids may hinder the market growth.

SWOT Analysis
Strength:
- Increasing prevalence of lupus globally which is creating high demand for effective therapeutics.
- Advancements in research and development leading to discovery of novel drug targets and pathways for treatment.
- Growing awareness about the disease and available treatment options.

Weakness:
- High cost of biologic lupus drugs posing affordability challenges.
- Risk of adverse effects and toxicity with long-term use of certain drugs.

Opportunity:
- Expanding therapeutic pipeline with drugs targeting new pathways and mechanisms of action.
- Emergence of biosimilars providing cost-effective alternatives.

Threats:
- Stringent regulatory policies delaying product approvals.
- Threat from generic competition once patents of major drugs expire.

Key Takeaways
The Global Lupus Therapeutics Market Size is expected to witness high growth, exhibiting CAGR of 8.6% over the forecast period, due to increasing prevalence of systemic lupus erythematosus (SLE) worldwide. As per estimates, around 5 million people globally suffer from lupus annually.

Regional analysis:
North America currently dominates the global market and is expected to continue its dominance over the forecast period. This is attributed to growing lupus patient population, rising research activities, and availability of advanced treatment options in the region. However, Asia Pacific is anticipated to emerge as the fastest growing regional market propelled by rising healthcare expenditure, increasing disposable incomes, and growing awareness.

Key players:
Key players operating in the lupus therapeutic market are Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh. These players are focusing on new drug developments and product launches to strengthen their market position.

For More Insights, Read: https://www.trendingwebwire.com/lupus-therapeutic-market-trends-growth-and-regional-outlook-2023-2030/